联合临床药物动力学。

文章的细节

引用

复制到剪贴板

Roila F,德尔Favero

联合临床药物动力学。

Pharmacokinet。1995年8月,29 (2):95 - 109。doi: 10.2165 / 00003088-199529020-00004。

PubMed ID

7586904 (在PubMed

]

文摘

联合是一个强有力的和高度选择性5 -羟色胺5-HT3-receptor拮抗剂已证明重要的止吐剂活动和良好的耐受性在预防化疗所致的恶心和呕吐。联合是完全,口服后迅速从胃肠道吸收,并与重复口服不积累。由于肝初步的代谢,其生物利用度仅为60%,联合由注入超过15分钟。beplayapp生物利用度略有增加后,管理标准,并不是共同服用制酸剂的影响;稍微增强生物利用度一直在观察癌症患者。由于时间达到峰值浓度是0.5到2小时口服摄入后,药物应化疗前至少30分钟。可能的替代方式管理联合包括肌肉、皮下和直肠管理和口服缓释制剂。分布的联合分布广泛(体积大约160 l)和结合适度(70 - 76%)血浆蛋白;消除半衰期平均大约3.8 + / - 1小时。间隙发生肝代谢(95%),而不是肾排泄。 Metabolites do not play a role in the activity of the drug, and there is no evidence of genetic polymorphic metabolism. Although aging is associated with decreased clearance and increased bioavailability, dosage adjustments are not required for the elderly, and may be necessary only in patients with severe hepatic impairment. Chemotherapeutic agents do not seem to modify the pharmacokinetics of ondansetron. There remains the question of whether control of emesis is related to systemic availability of ondansetron and, in consequence, the optimal dose and schedule of ondansetron is still to be identified with certainty.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

联合